Journal article · 2025 · Open access

Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease

Xingtao Zhao, Ruolan Li, Ruiqi Sun, Qiong Pan, Hongyan Lu, Jin Chai

EngMedicine, 2(3), 100088 · Published 3 July 2025 · DOI 10.1016/j.engmed.2025.100088

Open full textCite this paper

In brief

“Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease” is a 2025 journal article by Xingtao Zhao and 5 co-authors, published in EngMedicine. OpenAlex counts 14 citations as of 21 November 2026, which puts it in the top 8% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at EngMedicine.

Citations
14
Most cited in
2026 (12)
Field-weighted impact
2.74
References
164
Authors
6

Abstract

Cholestatic liver disease (CSLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) are both associated with abnormal bile acid (BA) metabolism and have a steadily increasing incidence and prevalence worldwide. BAs are amphiphilic cholesterol metabolites that are pivotal in the regulation of their own biosynthesis as well as gut microbiota, indirectly affecting both host immunity and metabolic homeostasis. Conversely, the composition and function of BAs, including their reabsorption and excretion, are regulated by gut microbiota. Thus, regulating gut microbiota or targeting BA metabolic pathways is expected to provide novel strategies for the treatment of liver diseases. The present review focuses on elucidating the critical roles of the gut microbiota-BA axis in CSLD and MASLD and its potential as a therapeutic target. First, we clarify the roles of gut microbiota, BAs, and BA receptors, mainly farnesoid X receptor (FXR) and G protein-coupled BA receptor 1 (TGR5), in the modulation of hepatic glucose, lipid, and amino acid metabolism and intestinal barrier function, which effectively maintains the balance of the host immunoinflammatory response, as well as different cell death pathways. We also summarize recent preclinical and clinical studies involving the gut microbiota-BA axis. Subsequently, we emphasize the indirect regulation of BA metabolism by targeting gut microbiota through dietary interventions, fecal microbiota transplantation (FMT), and bacteriophage therapy and direct regulation of BA signaling by targeting secondary BAs, BA receptor agonists (fibroblast growth factor [FGF]19/21), and inhibitors of BA transporters (apical sodium-dependent BA transporter [ASBT], sodium taurocholate co-transporting polypeptide [NTCP]). Finally, we summarize and discuss mainly nanoparticle-based therapeutic strategies for modulating BA metabolism and the composition and function of the gut microbiota. Therefore, this review provides new insights to better understand the gut microbiota-BA axis in the context of treating CSLD and MASLD. • The gut microbiota modulates BAs to regulate hepatic metabolism. • Diversity of BA modifications affect the intestinal microenvironment. • Targeting the gut-BA axis could lead to promising treatments for CSLD and MASLD.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025). Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease. EngMedicine, 2(3), 100088. https://doi.org/10.1016/j.engmed.2025.100088

MLA 9

Zhao, Xingtao, et al. “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease.” EngMedicine, vol. 2, no. 3, 2025, p. 100088. https://doi.org/10.1016/j.engmed.2025.100088.

Chicago

Zhao, Xingtao, Ruolan Li, Ruiqi Sun, Qiong Pan, Hongyan Lu, and Jin Chai. 2025. “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease.” EngMedicine 2 (3): 100088. https://doi.org/10.1016/j.engmed.2025.100088.

Harvard

Zhao, X. et al. (2025) ‘Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease’, EngMedicine, 2(3), p. 100088. doi:10.1016/j.engmed.2025.100088.

IEEE

X. Zhao, R. Li, R. Sun, Q. Pan, H. Lu, and J. Chai, “Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease,” EngMedicine, vol. 2, no. 3, p. 100088, 2025, doi: 10.1016/j.engmed.2025.100088.

BibTeX

@article{zhao2025targeting,
  title     = {{Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease}},
  author    = {Zhao, Xingtao and Li, Ruolan and Sun, Ruiqi and Pan, Qiong and Lu, Hongyan and Chai, Jin},
  journal   = {EngMedicine},
  year      = {2025},
  volume    = {2},
  number    = {3},
  pages     = {100088},
  doi       = {10.1016/j.engmed.2025.100088},
  url       = {https://doi.org/10.1016/j.engmed.2025.100088}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health

  • cholestatic liver disease
  • non-alcoholic fatty liver disease
  • bile acid metabolism
  • farnesoid X receptor
  • TGR5
  • bile acid receptors
  • ASBT
  • normal tissue complication probability

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Zhao, X., Li, R., Sun, R., Pan, Q., Lu, H., & Chai, J. (2025). Targeting the gut microbiota-bile acid axis: Therapeutic strategies for cholestatic liver disease and metabolic dysfunction-associated steatotic liver disease. EngMedicine, 2(3), 100088. https://doi.org/10.1016/j.engmed.2025.100088

How many times has this paper been cited?

14 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at EngMedicine: sign in and open the full text from this page.

Who wrote this paper?

Xingtao Zhao, Ruolan Li, Ruiqi Sun, Qiong Pan, Hongyan Lu, Jin Chai.

What is the DOI of this paper?

10.1016/j.engmed.2025.100088, permanently at https://doi.org/10.1016/j.engmed.2025.100088. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.